Radius Health, a US-based developer of drug therapies for osteoporosis and women’s health, plans to sell 6.5 million shares at between $8.50 and $10.50 each in its Nasdaq stock exchange flotation.
Investment banks UBS and Leerink Swann are co-lead underwriters of Radius’ initial public offering (IPO) that will give the company a $283m market capitalisation at $9.50 per share.
Radius Health has raised more than $170m from its venture backers and its shareholders include drugs company Ipsen Pharma.
Radius initially…
